PerpEquities

Equity · Healthcare

Moderna, Inc. (MRNA) perpetual futures

MRNA perpetual futures on 23 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade MRNAUSDT.

Moderna is a biotechnology firm developing mRNA-based therapies and vaccines for infectious diseases, cancer, rare, cardiovascular, and autoimmune conditions.

$227.71-7.8%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · Deepcoin (MRNA/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

23/23 live markets
Venues
23
Live markets
23/23
24h volume
$85.7MCoverage: 19/23 marketsExchange-reported volume: $99.4M
Open interest
$24.1MCoverage: 20/23 markets
Best liquidity
$6.3M
LBank
Tightest spread
+1.3 bps
Hyperliquid HIP-3
Highest volume
$23.3M
Deepcoin
Settlement mix
USDT · 18/23
Perp/spot vol.
0.02x
Spot volume $4.9B
OI / float
+0.03%
Float $84.7B
Spot performance
1D-7.82%
5D+0.24%
1M+41.53%
6M+305.83%
YTD+639.27%
1Y+700.33%

Venue matrix

23 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BinanceTradeMRNA/USDTTrading$227.710.0% APR
0.000% every 8h
+3.1 bps-$19.4M$2.6MUSDT-
Hyperliquid HIP-3Tradexyz:MRNATrading$227.36+5.5% APR
+0.00063% every 1h
+1.3 bps$171.1K$19.3M$4.4MUSDC10x
OKXTradeMRNA/USDTTrading$227.650.0% APR
0.000% every 8h
+3.1 bps$84K$6.2M$1.7MUSDT20x
XT.comTradeMRNA/USDTTrading$227.71+11.0% APR
+0.010% every 8h
+5.3 bps$113.5K$5.2M$5.3MUSDT20x
BitgetTradeMRNA/USDTTrading$227.840.0% APR
0.000% every 8h
+2.6 bps-$4.3M$930.6KUSDT20x
MEXCTradeMRNA/USDTTrading$227.710.0% APR
0.000% every 8h
+4.8 bps$171.2K$3.9M$5.1MUSDT50x
BybitTradeMRNA/USDTTrading$227.710.0% APR
0.000% every 8h
+8.3 bps$38.7K$1.8M$629.4KUSDT25x
PhemexTradeMRNA / USDTTrading$227.770.0% APR
0.000% every 8h
+4.4 bps$32.7K$738.4K$1.6MUSDT20x
BitunixTradeMRNA/USDTTrading$227.74+21.9% APR
+0.020% every 8h
+10.5 bps$287.4K$545.2K$73.4KUSDT20x
Gate.ioTradeMRNA/USDTTrading$227.810.0% APR
0.000% every 8h
+3.1 bps-$354.1K$1.3MUSDT20x
HTXTradeMRNA/USDTTrading$227.56-+57.2 bps$149.8K$190.9K-USDT-
Helix (Injective)TradeMRNA/USDCTrading$227.66+24.1% APR
+0.00275% every 1h
--$147.7K-USDC12x
Ondo PerpsTradeMRNA/USDTrading$227.24-+11.0 bps$452.9K$112.7K$53.6KUSDC5x
GRVTTradeMRNA/USDTTrading$227.760.0% APR
0.000% every 8h
+4.8 bps$83.6K$101.8K$587.6USDT-
AsterTradeMRNAUSDTTrading$227.550.0% APR
0.000% every 8h
+109.7 bps$24.9K$85.4K$30KUSDT-
BloFinTradeMRNA/USDTTrading$227.73+3.2% APR
+0.00293% every 8h
+2.2 bps$504.7K$45.3K$105.7KUSDT20x
ExtendedTradeMRNA/USDTrading$227.34+5.3% APR
+0.00060% every 1h
+14.9 bps$59.9K$17.9K$13.7KUSD10x
Crypto.com ExchangeTradeMRNA/USDTrading$227.13-13.5% APR
-0.00155% every 1h
+12.3 bps$7.3K$10.2K$3.7KUSD50x
DeepcoinTradeMRNA/USDTTrading$227.79-11.0% APR
-0.010% every 8h
+14.9 bps$1.5M$23.3M-USDT25x
OurbitTradeMRNA/USDTTrading$227.720.0% APR
0.000% every 8h
+3.5 bps$88.7K$8.9M⚠$149.3KUSDT50x
LBankTradeMRNA/USDTTrading$227.710.0% APR
0.000% every 8h
+1.8 bps$6.3M$1.7M⚠$56.9KUSDT50x
BingXTradeMRNA-USDTTrading$227.71-5.5% APR
-0.00500% every 8h
+3.1 bps$754.7K$1.6M⚠$21.6KUSDT-
KuCoinTradeMRNA/USDTTrading$227.770.0% APR
0.000% every 8h
+26.7 bps$10.1K$1.5M⚠$38.8KUSDT20x

Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Broad liquidity · 17 of 23 venues absorb $10k · Typical cost: +9.1 bps – +18.3 bps

Too thin: KuCoin, Crypto.com Exchange

No fresh book data: Aster, Bitget, Gate.io, Helix (Injective)

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 39m ago
Market cap
$90.6B
Updated 39m ago
Revenue
$2.2B
Trailing 12 months
Revenue growth
+8%
Next fiscal year
Profit margin
-141.4%
P/E
-28.4
Peer P/E 23.5
Free cash flow
-$1.2B
Trailing 12 months
More metrics
Net income
-$3.2B
Trailing 12 months
P/S
40.7
Peer P/E
23.5
Similar listed perps
Revenue estimate
$2.1B
Next fiscal year
Earnings
2026-11-06
Revenue est. $892.4M · Updated 39m ago
Dividend
-

Fundamental detail

Annual + quarterly
Latest revenue$1.9B
Net margin-145.2%
Free cash flow-$2.1B
Net debt-$679M
2020$803.4M
2021$17.7B
2022$18.9B
2023$6.8B
2024$3.2B
2025$1.9B
PeriodRevenueGrowthNet incomeFCF
2020$803.4M+1,234%-$747.1M$2B
2021$17.7B+2,108%$12.2B$13.3B
2022$18.9B+6%$8.4B$4.6B
2023$6.8B-64%-$4.7B-$3.8B
2024$3.2B-53%-$3.6B-$4.1B
2025$1.9B-39%-$2.8B-$2.1B
PeriodGross marginOperating marginNet marginROEROA
2020+95.1%-95.0%-93.0%-29.2%-10.2%
2021+85.2%+75.0%+68.8%+86.3%+49.5%
2022+71.3%+49.9%+44.3%+43.7%+32.3%
2023+31.5%-61.9%-68.8%-34.0%-25.6%
2024+54.2%-123.3%-111.3%-32.7%-25.2%
2025+55.3%-158.1%-145.2%-32.6%-22.9%
PeriodCashDebtNet debtCurrent ratio
2020$2.6B$237M-$2.4B1.43
2021$6.8B$916M-$5.9B1.76
2022$3.2B$1.2B-$2B2.73
2023$2.9B$1.2B-$1.7B3.42
2024$1.9B$747M-$1.2B3.67
2025$2.6B$1.9B-$679M3.29
PeriodMarket capEnterprise valueP/SP/E
2020$39.8B$37.5B49.6-53.3
2021$102.4B$96.4B5.88.4
2022$70.8B$68.8B3.78.4
2023$38B$36.3B5.5-8.1
2024$16B$14.8B5.0-4.5
2025$11.5B$10.8B5.9-4.1
Q3 2024$1.9B
Q4 2024$956M
Q1 2025$107M
Q2 2025$142M
Q3 2025$1B
Q4 2025$678M
Q1 2026$389M
Q2 2026$145M
PeriodRevenueGrowthNet incomeFCF
Q3 2024$1.9B+1%$13M-$1.7B
Q4 2024$956M-66%-$1.1B$303M
Q1 2025$107M-36%-$971M-$1.2B
Q2 2025$142M-36%-$825M-$922M
Q3 2025$1B-45%-$200M-$880M
Q4 2025$678M-29%-$826M$912M
Q1 2026$389M+264%-$1.3B-$692M
Q2 2026$145M+2%-$782M-$563M
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+72.3%-3.8%+0.7%+0.1%+0.1%
Q4 2024+22.7%-130.3%-117.2%-10.3%-7.9%
Q1 2025+15.9%-981.3%-907.5%-9.6%-7.6%
Q2 2025+16.2%-638.7%-581.0%-8.8%-6.9%
Q3 2025+0.8%-25.6%-19.7%-2.1%-1.6%
Q4 2025+33.3%-126.4%-121.8%-9.5%-6.7%
Q1 2026-145.5%-356.8%-345.2%-18.1%-11.7%
Q2 2026+35.9%-562.1%-539.3%-11.6%-7.1%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$1.6B$1.4B-$289M4.39
Q4 2024$1.9B$747M-$1.2B3.67
Q1 2025$1.6B$745M-$878M4.22
Q2 2025$1.3B$741M-$538M3.93
Q3 2025$1.1B$1.4B$261M3.93
Q4 2025$2.6B$1.9B-$679M3.29
Q1 2026$1.9B$1.3B-$610M2.41
Q2 2026$1.7B$1.3B-$436M2.29
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$25.7B$25.4B13.9494.3
Q4 2024$16B$14.8B16.7-3.6
Q1 2025$10.9B$10.1B102.3-2.8
Q2 2025$10.7B$10.2B75.4-3.2
Q3 2025$10.1B$10.3B9.9-12.7
Q4 2025$11.6B$10.9B17.1-3.5
Q1 2026$20.1B$19.5B51.6-3.7
Q2 2026$27.7B$27.3B191.3-8.9

Refreshed 39m ago

Charts: revenue, profit, cash flow & valuation
Revenue$145MQ2 2026
$703.3M$1.4B$2.1B$2.8BQ3 2023: $1.8BQ4 2023: $2.8BQ1 2024: $167MQ2 2024: $221MQ3 2024: $1.9BQ4 2024: $956MQ1 2025: $107MQ2 2025: $142MQ3 2025: $1BQ4 2025: $678MQ1 2026: $389MQ2 2026: $145MQ3 2023Q2 2026
Net income-$782MQ2 2026
-$2.7B-$1.7B-$744.8M$217MQ3 2023: -$3.6BQ4 2023: $217MQ1 2024: -$1.2BQ2 2024: -$1.3BQ3 2024: $13MQ4 2024: -$1.1BQ1 2025: -$971MQ2 2025: -$825MQ3 2025: -$200MQ4 2025: -$826MQ1 2026: -$1.3BQ2 2026: -$782MQ3 2023Q2 2026
EBITDA-$704MQ2 2026
-$1.2B-$710.5M-$216.3M$278MQ3 2023: -$1.7BQ4 2023: $278MQ1 2024: -$1.1BQ2 2024: -$1.2BQ3 2024: $79MQ4 2024: -$1.1BQ1 2025: -$924MQ2 2025: -$760MQ3 2025: -$135MQ4 2025: -$732MQ1 2026: -$1.3BQ2 2026: -$704MQ3 2023Q2 2026
Free cash flow-$563MQ2 2026
-$1.1B-$414M$249M$912MQ3 2023: -$1.7BQ4 2023: $402MQ1 2024: -$1.2BQ2 2024: -$1.5BQ3 2024: -$1.7BQ4 2024: $303MQ1 2025: -$1.2BQ2 2025: -$922MQ3 2025: -$880MQ4 2025: $912MQ1 2026: -$692MQ2 2026: -$563MQ3 2023Q2 2026
EPS-$1.96Q2 2026
-$7.01-$4.49-$1.97$0.55Q3 2023: -$9.53Q4 2023: $0.55Q1 2024: -$3.08Q2 2024: -$3.33Q3 2024: $0.03Q4 2024: -$2.91Q1 2025: -$2.52Q2 2025: -$2.13Q3 2025: -$0.51Q4 2025: -$2.11Q1 2026: -$3.4Q2 2026: -$1.96Q3 2023Q2 2026
Cash / Debt$1.7BQ2 2026
$733M$1.5B$2.2B$2.9BQ3 2023 · Cash: $2.9BQ3 2023 · Debt: $1.5BQ4 2023 · Cash: $2.9BQ4 2023 · Debt: $1.2BQ1 2024 · Cash: $2.1BQ1 2024 · Debt: $1.2BQ2 2024 · Cash: $2.5BQ2 2024 · Debt: $1.3BQ3 2024 · Cash: $1.6BQ3 2024 · Debt: $1.4BQ4 2024 · Cash: $1.9BQ4 2024 · Debt: $747MQ1 2025 · Cash: $1.6BQ1 2025 · Debt: $745MQ2 2025 · Cash: $1.3BQ2 2025 · Debt: $741MQ3 2025 · Cash: $1.1BQ3 2025 · Debt: $1.4BQ4 2025 · Cash: $2.6BQ4 2025 · Debt: $1.9BQ1 2026 · Cash: $1.9BQ1 2026 · Debt: $1.3BQ2 2026 · Cash: $1.7BQ2 2026 · Debt: $1.3BQ3 2023Q2 2026
CashDebt
Profitability+35.9%Q2 2026
-717.9%-454.5%-191.1%+72.3%Q3 2023 · Gross margin: -22.4%Q4 2023 · Gross margin: +67.0%Q1 2024 · Gross margin: +42.5%Q2 2024 · Gross margin: +48.0%Q3 2024 · Gross margin: +72.3%Q4 2024 · Gross margin: +22.7%Q1 2025 · Gross margin: +15.9%Q2 2025 · Gross margin: +16.2%Q3 2025 · Gross margin: +0.8%Q4 2025 · Gross margin: +33.3%Q1 2026 · Gross margin: -145.5%Q2 2026 · Gross margin: +35.9%Q3 2023 · Operating margin: -109.9%Q4 2023 · Operating margin: +0.2%Q1 2024 · Operating margin: -758.1%Q2 2024 · Operating margin: -616.7%Q3 2024 · Operating margin: -3.8%Q4 2024 · Operating margin: -130.3%Q1 2025 · Operating margin: -981.3%Q2 2025 · Operating margin: -638.7%Q3 2025 · Operating margin: -25.6%Q4 2025 · Operating margin: -126.4%Q1 2026 · Operating margin: -356.8%Q2 2026 · Operating margin: -562.1%Q3 2023 · Net margin: -198.3%Q4 2023 · Net margin: +7.7%Q1 2024 · Net margin: -703.6%Q2 2024 · Net margin: -578.7%Q3 2024 · Net margin: +0.7%Q4 2024 · Net margin: -117.2%Q1 2025 · Net margin: -907.5%Q2 2025 · Net margin: -581.0%Q3 2025 · Net margin: -19.7%Q4 2025 · Net margin: -121.8%Q1 2026 · Net margin: -345.2%Q2 2026 · Net margin: -539.3%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+2.1%Q2 2026
+16.4%+98.8%+181.2%+263.6%Q2 2024: -35.8%Q3 2024: +1.3%Q4 2024: -66.0%Q1 2025: -35.9%Q2 2025: -35.7%Q3 2025: -45.2%Q4 2025: -29.1%Q1 2026: +263.6%Q2 2026: +2.1%Q3 2023Q2 2026
Shares outstanding396MQ2 2026
99.8M199.5M299.3M399MQ3 2023: 381MQ4 2023: 395MQ1 2024: 382MQ2 2024: 384MQ3 2024: 399MQ4 2024: 385MQ1 2025: 386MQ2 2025: 388MQ3 2025: 390MQ4 2025: 392MQ1 2026: 395MQ2 2026: 396MQ3 2023Q2 2026
Valuation-8.9Q2 2026
114.1240.8367.6494.3Q3 2023 · P/E: -2.7Q4 2023 · P/E: 43.6Q1 2024 · P/E: -8.6Q2 2024 · P/E: -8.7Q3 2024 · P/E: 494.3Q4 2024 · P/E: -3.6Q1 2025 · P/E: -2.8Q2 2025 · P/E: -3.2Q3 2025 · P/E: -12.7Q4 2025 · P/E: -3.5Q1 2026 · P/E: -3.7Q2 2026 · P/E: -8.9Q3 2023 · P/S: 21.5Q4 2023 · P/S: 13.5Q1 2024 · P/S: 241.6Q2 2024 · P/S: 201.5Q3 2024 · P/S: 13.9Q4 2024 · P/S: 16.7Q1 2025 · P/S: 102.3Q2 2025 · P/S: 75.4Q3 2025 · P/S: 9.9Q4 2025 · P/S: 17.1Q1 2026 · P/S: 51.6Q2 2026 · P/S: 191.3Q3 2023Q2 2026
P/EP/S
Revenue$1.9B2025
$4.7B$9.4B$14.2B$18.9B2018: $135.1M2019: $60.2M2020: $803.4M2021: $17.7B2022: $18.9B2023: $6.8B2024: $3.2B2025: $1.9B20182025
Net income-$2.8B2025
-$485M$3.7B$8B$12.2B2018: -$384.7M2019: -$514M2020: -$747.1M2021: $12.2B2022: $8.4B2023: -$4.7B2024: -$3.6B2025: -$2.8B20182025
EBITDA-$2.6B2025
$838.3M$5.1B$9.3B$13.5B2018: -$412.1M2019: -$477.1M2020: -$703.6M2021: $13.5B2022: $10B2023: -$3.3B2024: -$3.4B2025: -$2.6B20182025
Free cash flow-$2.1B2025
$292.8M$4.6B$9B$13.3B2018: -$436.6M2019: -$490.5M2020: $2B2021: $13.3B2022: $4.6B2023: -$3.8B2024: -$4.1B2025: -$2.1B20182025
EPS-$7.262025
-$2.18$7.97$18.1$28.32018: -$1.172019: -$1.552020: -$1.962021: $28.32022: $20.12023: -$12.32024: -$9.272025: -$7.2620182025
Cash / Debt$2.6B2025
$1.7B$3.4B$5.1B$6.8B2018 · Cash: $658.4M2018 · Debt: $33.5M2019 · Cash: $235.9M2019 · Debt: $132.4M2020 · Cash: $2.6B2020 · Debt: $237M2021 · Cash: $6.8B2021 · Debt: $916M2022 · Cash: $3.2B2022 · Debt: $1.2B2023 · Cash: $2.9B2023 · Debt: $1.2B2024 · Cash: $1.9B2024 · Debt: $747M2025 · Cash: $2.6B2025 · Debt: $1.9B20182025
CashDebt
Profitability+55.3%2025
-656.0%-405.6%-155.3%+95.1%2018 · Gross margin: +81.6%2019 · Gross margin: +48.5%2020 · Gross margin: +95.1%2021 · Gross margin: +85.2%2022 · Gross margin: +71.3%2023 · Gross margin: +31.5%2024 · Gross margin: +54.2%2025 · Gross margin: +55.3%2018 · Operating margin: -347.1%2019 · Operating margin: -906.4%2020 · Operating margin: -95.0%2021 · Operating margin: +75.0%2022 · Operating margin: +49.9%2023 · Operating margin: -61.9%2024 · Operating margin: -123.3%2025 · Operating margin: -158.1%2018 · Net margin: -284.8%2019 · Net margin: -853.7%2020 · Net margin: -93.0%2021 · Net margin: +68.8%2022 · Net margin: +44.3%2023 · Net margin: -68.8%2024 · Net margin: -111.3%2025 · Net margin: -145.2%20182025
Gross marginOperating marginNet margin
Revenue growth-39.2%2025
+479.1%+1,022.0%+1,564.8%+2,107.6%2019: -55.4%2020: +1,234.3%2021: +2,107.6%2022: +6.4%2023: -63.7%2024: -53.3%2025: -39.2%20182025
Shares outstanding389M2025
107.8M215.5M323.3M431M2018: 328.8M2019: 330.8M2020: 381.3M2021: 431M2022: 416M2023: 382M2024: 384M2025: 389M20182025
Valuation-4.12025
-13.127.167.3107.52018 · P/E: -13.12019 · P/E: -12.62020 · P/E: -53.32021 · P/E: 8.42022 · P/E: 8.42023 · P/E: -8.12024 · P/E: -4.52025 · P/E: -4.12018 · P/S: 37.22019 · P/S: 107.52020 · P/S: 49.62021 · P/S: 5.82022 · P/S: 3.72023 · P/S: 5.52024 · P/S: 5.02025 · P/S: 5.920182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-11-06
Revenue est. $892.4M · Updated 39m ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-8.31$2.1B+8%17
FY 2027-4.74$2.4B+25%17
FY 2028-2.72$3.4B+76%15
FY 20290.50$5.6B+186%9
FY 20303.42$7.6B+289%6
Q3 2026-1.09$892.4M-12%11

Company events

6
2026-11-06EarningsActual - / Estimate -1.09-
2026-07-31EarningsActual -1.97 / Estimate -2.03Beat
2026-05-01EarningsActual -3.4 / Estimate -4.45Beat
2026-02-13EarningsActual -2.11 / Estimate -2.54Beat
2025-11-06EarningsActual -0.51 / Estimate -1.87Beat
2025-08-01EarningsActual -2.13 / Estimate -2.99Beat

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Oct 16, 2026, 09:17 PM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
Stéphane Bancel
Employees
4,700
IPO date
Dec 7, 2018
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei12.71
Piotroski scorei2/9
FMP ratingiC-
Owner earningsi-$562.23M-$1.42 per share
ESG risk ratingiBIndustry rank: 637 out of 728

Rating factors

Return on equityi
1
Return on assetsi
1
Debt to equityi
2
Price to earningsi
1
Price to booki
2
Market cap history
$84.30B+238.0%Jul 26 – Oct 26
$21.84B$53.24B$84.64BHigh: $84.64B · 2026-10-12Low: $21.84B · 2026-08-03Latest: $84.30B · 2026-10-16Jul 26Aug 26Sep 26Oct 26
Latest: $84.30B · 2026-10-16High: $84.64B · 2026-10-12Low: $21.84B · 2026-08-03
Largest fund holders
FundWeightShares held
ANNPX1.22%15.8M
VTI0.09%11.4M
VOO0.11%9.8M
QQQ0.38%8.3M
FDGRX1.18%5.4M
IVV0.13%4.9M
XUU.TO0.11%4.9M
SPY0.13%4.6M
VWIGX0.69%4.5M
VB0.44%4M
VO0.34%3.8M
NCV0.74%3.5M

Analyst track record

How the analysts covering MRNA have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings212528
Analysts2839
Buy / hold / sell17 / 161 / 34107 / 335 / 86
Upgrades / downgrades / initiations4 / 3 / 28 / 12 / 9
Price targets hit / missed173 / 0 (100%)429 / 4 (99%)
Avg. return after a rating (TipRanks)+553.3%+414.1%
Best / worst call+1,870.8% / +31.4%+1,870.8% / -23.7%

After buy calls on this stock: median 21-day move -2.9% vs S&P 500 -4.1% (n = 113)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Tim AndersonBank of America Securities100% hit rate on this stock · 8 targets measuredSelltarget $21.00Nov 10, 2025
  2. Luca IssiRBC Capital78% hit rate on this stock · 9 targets measuredHoldtarget $130Oct 16, 2026
  3. Mani ForooharLeerink Partners70% hit rate on this stock · 20 targets measuredSelltarget $12.00Feb 11, 2026

Latest ratings

DateAnalystCallTarget
Oct 19, 2026Alec StranahanBank of America SecuritiesHoldMaintained$220
Oct 16, 2026Luca IssiRBC CapitalHoldMaintained$130
Oct 16, 2026Luca IssiRBC CapitalHoldMaintained$130
Oct 15, 2026Geoff MeachamCitiSellMaintained$80.00
Oct 15, 2026Salveen RichterGoldman SachsHoldReiterated$137
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$50.00$100$150$200Nov 25 · Buy 4 · Hold 16 · Sell 4Nov 25Dec 25 · Buy 4 · Hold 16 · Sell 4Jan 26 · Buy 2 · Hold 19 · Sell 5Jan 26Feb 26 · Buy 2 · Hold 19 · Sell 5Mar 26 · Buy 1 · Hold 19 · Sell 5Mar 26Apr 26 · Buy 1 · Hold 18 · Sell 4May 26 · Buy 1 · Hold 18 · Sell 3May 26Jun 26 · Buy 1 · Hold 18 · Sell 4Jul 26 · Buy 1 · Hold 15 · Sell 4Jul 26Aug 26 · Buy 3 · Hold 16 · Sell 2Sep 26 · Buy 3 · Hold 17 · Sell 3Sep 26Oct 26 · Buy 3 · Hold 15 · Sell 4Nov 25 · avg. target $42.00Dec 25 · avg. target $42.63Jan 26 · avg. target $39.95Feb 26 · avg. target $41.05Mar 26 · avg. target $33.20Apr 26 · avg. target $35.21May 26 · avg. target $41.28Jun 26 · avg. target $41.83Jul 26 · avg. target $45.25Aug 26 · avg. target $88.41Sep 26 · avg. target $102Oct 26 · avg. target $100Nov 25 · month-end close $25.98Dec 25 · month-end close $29.49Jan 26 · month-end close $44.07Feb 26 · month-end close $53.57Mar 26 · month-end close $50.80Apr 26 · month-end close $45.94May 26 · month-end close $47.19Jun 26 · month-end close $70.03Jul 26 · month-end close $54.82Aug 26 · month-end close $140Sep 26 · month-end close $193Oct 26 · month-end close $218

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Oct 19, 2026 · 212 ratings

Frequently asked questions

Where can I trade MRNA perpetual futures?

Moderna, Inc. (MRNA) perpetual futures trade on 23 crypto venues, including Deepcoin, Binance, Hyperliquid HIP-3. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade MRNA around the clock?

Yes. Unlike the underlying stock, MRNA perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on MRNA perpetuals?

Right now the MRNA perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to +11.0% across 23 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the MRNA perp price compare to the Moderna, Inc. stock?

The venue-median MRNA perp mark is $227.7 versus a reference stock price of $227.7, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a MRNA perpetual future?

A MRNA perpetual is a derivative that tracks the price of Moderna, Inc. with no expiry date. It lets you take long or short exposure to Moderna, Inc. on crypto venues, around the clock.

What is MRNAUSDT perpetual?

MRNAUSDT is the symbol most crypto exchanges use for the Moderna, Inc. perpetual settled in USDT (Tether). It tracks the MRNA share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

MRNA perpetuals · perpequities.comMRNA perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/mrna-perp"><img src="https://perpequities.com/badge/mrna-perp.svg" width="240" height="64" alt="MRNA perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of MRNA perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for MRNA — one email every Sunday.

Watchlist and alerts

Price and funding alerts for MRNA, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X